Dr. Freedland on Treating Early-Stage Prostate Cancer

Video

Stephen J. Freedland, MD, from Duke University School of Medicine, discusses the complications faced when treating men with early-stage prostate cancer.

Stephen J. Freedland, MD, Associate Professor of Surgery, Associate Professor in Pathology, Duke University School of Medicine, discusses the complications faced when treating men with early-stage prostate cancer.

Freedland notes that in the past few years there have been multiple new agents approved for advanced prostate cancer. Overall, the treatment choice for early-stage prostate cancer has remained hormonal therapy and likely will not change in the next 5 years, Freedland believes.

When administering androgen-deprivation therapy there are multiple expected adverse events, such as bone loss, cholesterol issues, and insulin intolerance. Despite the occurrence of these events, not every patient develops a bone fracture or a heart attack and proper preventive measures should be addressed with patients.

As a way to reduce the expected consequences of treating prostate cancer, Freedland stresses that physicians should promote the importance of healthy living and exercise.

Related Videos
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD
Daniel Spratt, MD
Daniel Spratt, MD
Philip J. Koo, MD
Patrick I. Borgen, MD
Anthony D'Amico MD, PhD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania